Table 4 Risk factors for ILD associated with gefitinib use and predictive factors for tumor response in Japanese patients as determined by studies in the literature
Reference | No. patients | No. cases ILD (%) | No. ILD deaths (%) | Risk factors for ILD | Response Proportion (%) | Predictive factors for tumor response |
|---|---|---|---|---|---|---|
National Cancer Center, Japan (2004) [20] | 112 | 6 (5.4) | 4 (3.6) | -Pre-existing pulmonary fibrosis | 33 | -No history of smoking -No history of thoracic radiotherapy |
Okayama Lung Cancer Study Group (2005) [21] | 330 | 15 (4.5) | 8 (2.4) | -PS 2–4 -Pre-existing pulmonary fibrosis -Prior thoracic irradiation | 22 | Not investigated |
AstraZeneca (2004) [22] | 3322 | 193 (5.8) | 83 (2.5) | -PS 2–4 -History of smoking -Coexisting IP -Prior chemotherapy | 7.8 | Not investigated |
West Japan Thoracic Oncology Group (2006) [23] | 1976 | 70 (3.5) | 31 (1.6) | -History of smoking -Male -Coexisting IP | 17.6 | -PS 0–1 -No history of smoking -Female -Adenocarcinoma -Metastatic disease |
AstraZeneca (2007) [24] | 1482 | 59 (4.0) | ILD-related deaths In patients with ILD were 31.6% | -PS 2–4 -History of smoking -Age >55 years -Recent NSCLC diagnosis, -Reduced normal lung on computed tomography scan -Preexisting chronic ILD -Concurrent cardiac disease | Not investigated | Not investigated |
Present study | 526 | 17 (3.2) | 7 (1.3) | No factors found to be significant | 18.2 | -Female -No previous chemotherapy -Low absolute neutrophil count -Adenocarcinoma |